Key Regulatory Requirements and Guidelines for the Registration of a Drug in Canada

Authors

  • Sharin Thomas Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Mudit Dixit Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Rohit Dixit Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India

DOI:

https://doi.org/10.37591/rrjodfdp.v2i2.327

Abstract

Drug product registration is an important step in the process of a drug development from raw material to finished product to making it available to the public. Drug regulatory authorities play an important role in this process. Health Canada is the regulatory authority in Canada which manages the drug submission and approval of drug product in Canada. The guidelines from the Food and Drugs Act and Regulations for drug products are reviewed. An application to Health Canada (HC) to market a new drug in Canada is done by the sponsoring pharmaceutical company; the application typically includes animal data, chemistry and manufacturing data, and the results from clinical trials of various phases. The Therapeutic Products Directorate (TPD) is responsible for the regulation of prescription and non-prescription pharmaceutical (i.e. chemically synthesized) products and medical devices. The Common Technical Document for Registration of Pharmaceuticals for Human Use (International Conference on Harmonization [ICH] Topic M4) was adopted by Health Canada, in 2003, for use in the preparation of drug regulatory activities. Module 1 is region specific, while Modules 2, 3, 4, and 5 are intended to be common for all regions. A regional component is included in Module 3. The review of information provided in a well-structured regulatory activity will improve the efficiency of the screening and review of that regulatory activity.

 

Keywords: Health Canada, TPD, ICH, Drug Product, NDS

Cite this Article

Thomas Sharin, Dixit Mudit, Dixit Rohit. Key Regulatory Requirements and Guidelines for the Registration of a Drug in Canada. Research & Reviews: A Journal of Drug Formulation, Development and Production, 2015; 2(2): 28–37p

Downloads

Published

2019-02-27

Issue

Vol. 2 No. 2 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.